Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its recent and first quarter 2011 business activities.
-Ironwood and its U.S. partner, Forest Laboratories, Inc., recently presented six linaclotide-related abstracts at the 2011 Digestive Disease Week (DDW) annual meeting in Chicago. These presentations were the first time that Ironwood and Forest discussed the full results of the two Phase 3 IBS-C clinical trials that were completed in the second half of 2010.
-Ironwood and Forest are on track to submit a New Drug Application (NDA) for linaclotide with the U.S. Food and Drug Administration for both the irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC) indications in the third quarter of 2011.
